GI Innovation CEO On Developing World’s First Microbiome-Biologics Combo

 
• By Jung Won Shin

With an ultimate goal to develop the world’s first microbiome and protein drug combination therapies using its platform technology, GI Innovation is rapidly progressing its protein drug pipeline in allergic diseases and cancer on the back of its expert teams and external partnerships, the South Korean bioventure’s CEO tells Scrip.

GI Innovation's drug pipeline GI301
GI Innovation's Novel Long-Acting IgE Trap -Fc Fusion Protein GI301 • Source: GI Innovation Inc.

More from South Korea

More from Focus On Asia